Dr Reddys Laboratories has received an order dated 12 November 2024, from COFEPRIS (Comisi�n Federal para la Protecci�n Contra Riesgos Sanitarios) health department of Mexico. The drug regulatory body of Mexico (Comisi�n Federal para la Protecci�n contra Riesgos Sanitarios) has imposed a penalty of MXN 651, 420 (~Rs 27 Lakh) on the Company for deviation from prescribed guidelinesin filing intimation of import of a reference standard for one of the company`s APIs. Additionally, the fine was imposed due to an error in the date of the invoice and also name of the reference standard Vs import license. Powered by Capital Market - Live News

Net profit of Dr Reddy`s Laboratories declined 15.28% to Rs 1255.70 crore in the quarter ended September 2024 as against Rs 1482.20 crore during the previous quarter ended September 2023. Sales rose 16.51% to Rs 8016.10 crore in the quarter ended September 2024 as against Rs 6880.20 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales8016.106880.20 17 OPM %25.9029.19 - PBDT2314.402292.20 1 PBT1917.401916.70 0 NP1255.701482.20 -15 Powered by Capital Market - Live News

Aurigene Oncology, a wholly-owned subsidiary of Dr. Reddy`s Laboratories has announced the Phase 1 results for Ribrecabtagene autoleucel (DRL-1801) from the SWASTH study - India`s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma. The study reported initial results from the first 8 patients. All patients were heavily pre-treated with median of 5.5 previous lines of treatment. Most patients had also received transplant in the past and had disease progression post-transplant. All 8 patients (100%) achieved clinical response, with 5/8 (62.5%) having achieved stringent complete response. With respect to safety, there were no high-grade events of Cytokine Release Syndrome (CRS) or neurotoxicity, in any of the patients.After reviewing the Phase 1 data, the Indian Regulatory Agency i.e., Drugs Controller General of India (DCGI), has given the nod to commence Phase 2 part of the trial. These results of Phase 1 were presented at the 21st annual meeting of the International Myeloma Society at Rio De Janeiro, Brazil, held recently.Ribrecabtagene autoleucel is an autologous anti-BCMA CAR-T therapy that utilizes a humanized single-domain antibody as the antigen binding domain and lentivirus as a vector. DRL-1801 for the clinical trials is manufactured at the CAR-T GMP manufacturing facility at Aurigene Oncology, Bangalore. Powered by Capital Market - Live News

Dr. Reddy`s Laboratories SA, Switzerland, (DRSA) a wholly owned subsidiary of  Dr Reddys Laboratories , has incorporated a new wholly-owned subsidiary in Denmark, named �Dr. Reddy`s Denmark ApS� on 04 October 2024. Accordingly, Dr. Reddy`s Denmark ApS is a step-down wholly-owned subsidiary of the Company. Powered by Capital Market - Live News

Dr Reddys Laboratories announced that its wholly owned subsidiary, Dr. Reddy`s Laboratories SA, Switzerland has completed the acquisition of Haleon plc`s global portfolio of consumer healthcare brands in the Nicotine Replacement Therapy (NRT) category outside of the United States, through the purchase of shares of Northstar Switzerland SARL (Northstar Switzerland), a Haleon group company. The cost of acquisition is a payment of upfront cash consideration of GBP 458 million. As part of this acquisition, Northstar Switzerland along with its wholly owned subsidiaries North Star OpCo Limited (United Kingdom) and North Star Sweden AB (Sweden) are now wholly-owned step-down subsidiaries of the Company with effect from 30 September 2024. The acquired portfolio consists of Nicotinell, a global leader in the NRT category with an extensive footprint in over 30 countries spanning Europe, Asia including Japan, and Latin America, and local market-leading brand names of the product - Nicabate in Australia, Thrive in Canada, and Habitrol in New Zealand and Canada. The portfolio is inclusive of all formats such as lozenge, patch, gum as well as pipeline products, in all applicable global markets outside of the United States. Powered by Capital Market - Live News